Sanofi and GSK are the latest to start a Covid-19 vaccine trial
Partners Sanofi and GlaxoSmithKline started a first clinical trial for their Covid-19 vaccine candidate, trailing a handful of rivals but bringing decades of experience to the process.
As STAT’s Helen Branswell reports, the two companies plan to enroll more than 400 volunteers in a Phase 1/2 trial conducted at 11 sites around the U.S. The study, which should wrap up in early December, would enable Phase 3 development.
Sanofi and GSK are months behind Moderna, AstraZeneca, and partners Pfizer and BioNTech, all of which are already in Phase 3. But the partners have what could amount to an advantage: Their Covid-19 vaccine uses the same technology behind Sanofi’s FDA-approved influenza vaccine, which might improve the odds of success.
Read more.
As STAT’s Helen Branswell reports, the two companies plan to enroll more than 400 volunteers in a Phase 1/2 trial conducted at 11 sites around the U.S. The study, which should wrap up in early December, would enable Phase 3 development.
Sanofi and GSK are months behind Moderna, AstraZeneca, and partners Pfizer and BioNTech, all of which are already in Phase 3. But the partners have what could amount to an advantage: Their Covid-19 vaccine uses the same technology behind Sanofi’s FDA-approved influenza vaccine, which might improve the odds of success.
Read more.
.png)
No hay comentarios:
Publicar un comentario